Anzeige
❌
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A3EFRZ | ISIN: US09077D2099 | Ticker-Symbol: AI10
NASDAQ
14.05.25 | 20:17
0,690 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOFRONTERA INC Chart 1 Jahr
5-Tage-Chart
BIOFRONTERA INC 5-Tage-Chart

Aktuelle News zur BIOFRONTERA INC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BIOFRONTERA INC Aktie jetzt für 0€ handeln
MiBiofrontera Inc. - 8-K, Current Report5SEC Filings
06.05.Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025265ACCESS NewswireWOBURN, MA / ACCESS Newswire / May 6, 2025 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products...
► Artikel lesen
01.05.Biofrontera Inc.: Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis173GlobeNewswire (Europe)The initiative is a social media challenge ahead of Global AK Awareness Day, on May 24, which supports the work of The Skin Cancer Foundation and EuromelanomaThe Hats On Challenge provides an opportunity...
► Artikel lesen
18.04.Biofrontera Inc. - 8-K, Current Report8SEC Filings
21.03.Biofrontera Inc. - 8-K, Current Report10SEC Filings
21.03.Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update662GlobeNewswire (Europe)Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company...
► Artikel lesen
20.03.Biofrontera Inc. - 10-K, Annual Report6SEC Filings
18.03.Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk173GlobeNewswire (Europe)First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area...
► Artikel lesen
11.03.Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 20257GlobeNewswire (USA)
21.01.Biofrontera Inc. - S-1, General form for registration of securities8SEC Filings
08.01.Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)280GlobeNewswire (Europe)Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically...
► Artikel lesen
23.12.24Biofrontera Inc. Announces 100 RhodoLED XL Machines Now Placed in US Market14GlobeNewswire (USA)
03.12.24Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference445ACCESS NewswireWOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic...
► Artikel lesen
22.11.24Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note35GlobeNewswire (USA)
22.11.24Biofrontera Inc. - 8-K, Current Report5SEC Filings
13.11.24Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update239GlobeNewswire (Europe)?Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ?Total...
► Artikel lesen
01.11.24Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024360ACCESS NewswireWOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT...
► Artikel lesen
31.10.24Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)264GlobeNewswire (Europe)First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant pCorrelates to data seen in Europe where sBCC is already incorporated...
► Artikel lesen
14.10.24Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)255GlobeNewswire (Europe)First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions.Data now being analyzed, interim...
► Artikel lesen
07.10.24FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment249GlobeNewswire (Europe)Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz®-PDT using the BF-RhodoLED or the RhodoLED XL lampSupplemental New Drug Application (sNDA) supported...
► Artikel lesen
Seite:  1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1